Pink Sheet is part of the Business Intelligence Division of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By


Keeping Track: US FDA Approves Emflaza And Parsabiv, Turns Down Opioid/Anti-Emetic Combo CL-108

Executive Summary

The latest drug development news and highlights from our FDA Performance Tracker.


Related Content

Amgen's Parsabiv Approved With Unusual Postmarketing Requirements
Marathon Gets Long-Known Duchenne Treatment On-Label, But Will Payers Respond?
Sarepta Eyes Patient Outcomes To Boost Exondys 51's European Review
Amgen's Parsabiv's EU Approval Contrasts With US FDA Rejection
Sanofi Working To Resolve GMP Issues That Derailed Sarilumab Approval
Keeping Track: Novartis, Calardius Pick Up Speed; ADMA Stumbles
Keeping Track: FDA Approves Epclusa, Designates Four Breakthrough Therapies, Files Burst Of Applications
Keeping Track: More Bumps On The Abuse-Deterrent Opioid Road
Marathon Looking To Go The Distance In DMD
Deals Shaping The Medical Industry, February 2013


Related Companies




Ask The Analyst

Please Note: You can also Click below Link for Ask the Analyst
Ask The Analyst

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts